AdipoGen Life Sciences

Purvalanol A

CHF 60.00
In stock
AG-CR1-2903-M0011 mgCHF 60.00
AG-CR1-2903-M0055 mgCHF 120.00
AG-CR1-2903-M02525 mgCHF 360.00
More Information
Product Details
Synonyms 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine; NG 60
Product Type Chemical
Properties
Formula

C19H25ClN6O

MW 388.9
CAS 212844-53-6
Purity Chemicals ≥98% (HPLC)
Appearance Off-white powder.
Solubility Soluble in DMSO (30mg/ml), ethanol (10mg/ml), DMF (50mg/ml), methanol or dichloromethane.
Identity Determined by 1H-NMR.
InChi Key PMXCMJLOPOFPBT-HNNXBMFYSA-N
Smiles ClC1=CC=CC(NC2=C3C(N(C(C)C)C=N3)=NC(N[C@@H](CO)C(C)C)=N2)=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Potent, cell permeable cyclin-dependent protein kinase (cdk) inhibitor. Inhibits human CDK1 (IC50=4nM), CDK2/cyclin A (IC50=70nM), Cdc2/cyclin B, CDK2/cyclin E (IC50=35nM), CDK4/cyclin D1 (IC50=850nM) as well as CDK5/p35 (IC50=75nM).
  • DYRK1A inhibitor (IC50=300nM).
  • Anticancer agent. Strong apoptotic and autophagy inducer which causes cell cycle arrest in the G1 and G2 phase in various cancer cell lines.
  • More membrane permeable than purvalanol B.
  • Shown to inhibit ABCB1 and ABCB2 transporters and useful in co-treatment with selected anticancer drugs.
Product References
  1. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors: N.S. Gray, et al.; Science 281, 533 (1998)
  2. The specificities of protein kinase inhibitors: An update: J. Bain, et al.; Biochem. J. 371, 199 (2003)
  3. Cellular effects of purvalanol A: A specific inhibitor of cyclin-dependent kinase activities: N. Villerbu, et al.; Int. J. Cancer 97, 761 (2002)
  4. Purvalanol A induces apoptosis and downregulation of antiapoptotic proteins through abrogation of phosphorylation of JAK2/STAT3 and RNA polymerase II: D. Iizuka, et al.; Anticancer Drugs 19, 565 (2008)
  5. Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src: T. Hikita, et al.; Genes to Cells 15, 1051 (2010)
  6. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone: J. Hofman, et al.; Pharmacol. Res. 65, 312 (2012)
  7. Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro: D. Cihalova, et al.; PLoS One 8, e83467 (2013)
  8. Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time-dependent manner in HCT116 colon cancer cells: A. Coker-Gurkan, et al.; Oncol. Rep. 33, 2761 (2015)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.